The KLHL7 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human SK-HEP-1 cell line, engineered for loss-of-function analysis of the KLHL7 gene. This heterogeneous cell pool abolishes KLHL7 function without single-cell cloning, preserving population diversity and providing a robust system to study the substrate-adaptor role of KLHL7 within the CUL3-RBX1 E3 ubiquitin ligase complex and its effects on ubiquitin-dependent proteostasis.
The parental SK-HEP-1 line, originally established from the ascitic fluid of a patient with liver adenocarcinoma, serves as a widely accepted model for hepatocellular carcinoma (HCC) and liver metastasis. Despite its atypical endothelial-like features, SK-HEP-1 retains epithelial characteristics and is extensively utilized in HCC research owing to its reproducible growth kinetics and well-characterized oncogenic signaling pathways, making it a suitable host for gene-editing studies focused on hepatic proteolytic networks.
KLHL7 functions as a substrate-specific adaptor for the CUL3-RBX1 E3 ubiquitin ligase, recruiting targets such as DEAD-box helicases, ciliary proteins, and cell cycle regulators for NEDD8-dependent ubiquitination and proteasomal degradation. Upstream regulators like oxidative stress, NRF2, and p38 MAPK integrate stress signals with KLHL7 activity, thereby controlling protein turnover that governs cell cycle progression and apoptosis.
In hepatocellular carcinoma, aberrant ubiquitin-proteasome function frequently drives oncogenesis by stabilizing pro-proliferative and anti-apoptotic proteins. The KLHL7 knockout in SK-HEP-1 cells provides a dedicated model to dissect how loss of this adaptor disrupts the turnover of cell cycle and apoptosis regulators in a liver cancer context, potentially identifying new therapeutic targets. Additionally, the genetic link between KLHL7 and retinitis pigmentosa enables cross-disease investigations into the proteostatic mechanisms underlying both neoplastic and degenerative disorders.
Researchers can utilize these polyclonal knockout cells in a range of assays, including Western blotting to detect substrate accumulation, in vitro ubiquitination assays to evaluate CRL activity, and colony formation or viability assays to assess tumorigenic potential. Flow cytometry-based cell cycle and apoptosis analyses further delineate KLHL7??s impact on proliferation and programmed cell death. This model is well suited for functional genomics, drug target validation, and high-content screening of proteasome inhibitors or CRL modulators. For technical inquiries or additional information, please contact Ascent Research.
